Rituxan injection drug use-results survey in ABO-incompatible liver transplantation recipients

Rituxan injection drug use-results survey in ABO-incompatible liver transplantation recipients - Rituxan injection drug use-results survey in ABO-incompatible liver transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021373

Enrollment

100

Registered

2016-03-07

Start date

2016-02-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ABO-incompatible liver transplantation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All the patients who have received rituximab for inhibition of antibody mediated rejection in ABO-incompatible liver transplantation

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Adverse drug reaction occurrences Rejection rate	—

Countries

Japan

Contacts

Public ContactJunko Sakamoto

Zenyaku Kogyo, Co., Ltd. Post-Marketing-Surveillance Pharmacovigilance & Quality Assurance Department

Junko_Sakamoto@mail.zenyaku.co.jp03-3946-1136

Outcome results